March 2026 | Prepared by Ada Cockpit
2026E represents midpoint of €45-47B guidance range
Bayer AG is a German multinational pharmaceutical and biotechnology company headquartered in Leverkusen, Germany, founded August 1, 1863. The company operates across three main divisions: Pharmaceuticals, Consumer Health, and Crop Science, serving as one of the world's largest pharmaceutical and biomedical companies with 88,078 employees globally (2024/2025).
Under CEO Bill Anderson (appointed June 2023), Bayer is executing a major turnaround focused on five strategic priorities:
The company faces near-term headwinds from Xarelto patent expiry (~€1.5 billion annual impact) and Monsanto litigation (~€11.8 billion total provisions), but is positioning for mid-single-digit pharma growth by 2027 and EBITDA margin expansion to ~30% by 2030.
Nubeqa and Kerendia achieved blockbuster status (>€1B each) in 2024, growing 78% and 74% respectively. Combined €2B revenue (2024) projected to exceed €2.5B (2026) and €7-10B (2030), offsetting Xarelto/Eylea patent cliff losses.
Phase III OCEANIC-STROKE trial met primary endpoint (November 2025): 26% reduction in recurrent stroke (csHR 0.74, P<0.0001) with no increase in major bleeding. Regulatory submissions planned 2026; potential €2-3B peak sales as Xarelto successor if approved 2026-2027.
$7.25 billion Roundup class settlement proposed (February 2026), with preliminary court approval granted March 2026 and final approval pending July 2026. Settlement provides declining capped annual payments over 21 years, offering financial certainty but burdening 2026 free cash flow (-€2.5 to -€1.5B). Total litigation provisions: €11.8 billion.
| Product | Indication | FY2024 Revenue | Growth (CPA) | Status |
|---|---|---|---|---|
| Xarelto | Anticoagulant (AFib, VTE) | €3.24B | -31.6% | ⚠️ Patent expired (US Feb 2025, EU Apr 2024) |
| Eylea | Wet AMD, DME | €3.06B | -3.7% | ⚠️ Biosimilar competition (patent expired Jun 2024) |
| Nubeqa | nmCRPC, mHSPC | >€1.0B | +78% | ✅ Blockbuster, patent protected |
| Kerendia | CKD in T2D | ~€1.0B | +74% | ✅ Blockbuster, patent protected |
| Lynkuet | Menopausal symptoms | Launched Nov 2025 | New | ✅ US approval Oct 2025, patent protected |
| Category | Key Brands | FY2024 Revenue | Growth (CPA) |
|---|---|---|---|
| Nutritionals | One-A-Day, Elevit, Berocca | €1.46B | -4% |
| Dermatology | Dr. Scholl's, Canesten, Bepanthen | €1.42B | +2% |
| Allergy & Cold | Claritin, Afrin, Alka-Seltzer | €1.17B | -3% |
| Digestive Health | Iberogast, Phillips', Rennie | €0.90B | +4% |
| Pain & Cardio | Aspirin, Aleve | €0.83B | +2% |
HIGHEST PRIORITY - Perfect Patient Finder Fit
Simple blood and urine tests (eGFR and albumin-to-creatinine ratio) can identify eligible patients. Ada's symptom assessment can flag T2D patients for kidney screening (not routine in primary care).
| Metric | US Market |
|---|---|
| Net Revenue per Patient/Year | $4,000-7,200 (after 40-60% rebates) |
| Patient Lifetime Value (10 years) | $40,000-72,000 |
| Ada Fee (8-12% Year 1) | $3,200-8,640 per patient found |
CKD progression to end-stage kidney disease (ESKD) requires dialysis/transplant (~$90,000+/year). 30% of diabetic CKD patients progress to ESKD within 10 years without intervention. Kerendia reduces kidney failure risk by 18% (FIDELIO-DKD: HR=0.82, P=0.001).
"Chronic kidney disease in type 2 diabetes is a silent epidemic - 90% of CKD patients don't know they have it. Yet it's easily detectable with simple blood and urine tests (eGFR and albumin), which only 30-40% of diabetics receive annually. Ada Patient Finder can bridge this massive screening gap and prevent progression to dialysis, saving lives and healthcare costs."
HIGH PRIORITY - Strong Commercial Opportunity
| Metric | US Market |
|---|---|
| Net Revenue per Patient/Year | $40,000-60,000 (after 40-60% rebates) |
| Patient Lifetime Value (3 years) | $120,000-180,000 |
| Ada Fee (8-12% Year 1) | $3,200-7,200 per patient found |
Nubeqa's superior CNS safety profile (no seizure risk vs. Xtandi/Erleada) makes the clinical case compelling. ARANOTE trial showed 46% reduction in progression or death in mHSPC.
"Prostate cancer progression to castration-resistant disease is often delayed or missed, costing lives. The median time from primary treatment to nmCRPC recognition is 6 years, and once metastasis occurs, median survival is only 8.3 months. Ada Patient Finder can identify high-risk patients earlier through targeted PSA monitoring and symptom assessment."
| Product | Fit Score | Recommendation | Rationale |
|---|---|---|---|
| Eylea (Wet AMD) | 6/10 ⚠️ | MARGINAL | Biosimilar erosion, diagnostic pathway requires ophthalmology, limited screening gaps. Only pursue if Bayer requests with favorable terms. |
| Lynkuet (Menopause) | 4/10 ❌ | LOW PRIORITY | Not underdiagnosed - women self-identify hot flashes. Barriers are awareness/access, not identification. Patient Finder not the right tool. |
| Xarelto (Anticoagulation) | 2/10 ❌ | PASS | Post-patent (US Feb 2025, EU Apr 2024); generics active; commoditized market; no commercial value for patient finding. |
| Metric | 2026 Guidance |
|---|---|
| Group Sales | €45-47 billion (0-3% growth CPA) |
| EBITDA before special items | €9.1-10.1 billion |
| EBITDA Margin | 23-25% |
| Core EPS | €4.00-4.50 (down from €4.91 in 2025) |
| Net Financial Debt | €32-33 billion (up from €29.8B in 2025 due to litigation) |
| Free Cash Flow | -€2.5 to -€1.5 billion (negative due to litigation) |
Bayer trades at 65-70% discount to sum-of-parts valuation (~€36B market cap vs. €116-166B SOTP), primarily due to litigation overhang, patent cliff execution risk, and conglomerate discount.
| Valuation Metric | Bayer | Peer Average | Discount |
|---|---|---|---|
| EV/Sales (2026E) | 1.4-1.5x | 4.0-5.0x | (65-70%) |
| P/E (2026E Core EPS) | 8-11x | 15-20x | (45-50%) |
| EV/EBITDA (2026E) | 6.5-7.5x | 12-15x | (45-50%) |
| Company | Market Cap (USD) | 2024 Revenue (USD) | EV/Sales |
|---|---|---|---|
| Roche | $343B | ~$72B | ~4.8x |
| Novartis | $312B | ~$47B (pharma) | ~6.6x |
| AstraZeneca | $302B | ~$59B | ~5.1x |
| J&J (Pharma) | $368B (total) | ~$57B (pharma) | ~6.5x |
| Pfizer | $154B | ~$62B | ~2.5x |
| Bayer | $40-48B | ~$50B | ~1.4-1.5x |
+40-65% upside from current levels if:
Kerendia (CKD in Type 2 Diabetes) is an exceptional Patient Finder opportunity:
Nubeqa (Prostate Cancer) is a strong secondary opportunity:
Pursue if Kerendia successful or in parallel if resources allow.
Note: This report cites 83 sources total. Full reference list available in the markdown version of this report. All data verified as of March 2026; financial figures sourced from Bayer AG official investor relations materials and regulatory filings.